Fluorine is hardly new to medicinal chemistry. Yet it remains a conspicuous feature of newly approved medicines. A 2026 review of US FDA approvals identified fluorine in 14 of the 29 small-molecule drugs approved in 2025—nearly half the cohort.
That prevalence makes a strong case for fluorine's continued importance. It makes a much weaker case for fluorinating any given lead. A change that improves one property may compromise another, and an attractive analogue may be costly or difficult to manufacture consistently. The practical question is not whether fluorination works in general, but where its advantages justify the trade-offs.
Fluorine is commonplace. Its benefits are not guaranteed.
Medicinal chemists introduce fluorine for specific reasons: to adjust electronics or ionization, alter preferred conformations, change interactions with a target, or investigate a metabolic soft spot. The outcome depends on position, adjacent groups, and the rest of the molecule. The presence of a C–F bond is not, on its own, evidence of stronger potency or better exposure.
Fluorine featured in nearly half of the FDA’s new small-molecule approvals in 2025.
Number of small-molecule drugs in a published review’s 2025 approval cohort.
Consider suzetrigine, the Nav1.8 inhibitor approved in 2025. Its US prescribing information identifies fluorinated motifs, limited water solubility, and CYP3A-mediated metabolism. These features coexist in an approved drug; they do not establish what fluorine contributed relative to a nonfluorinated analogue. That distinction is central to good molecular design.
A small substitution can move several properties—and not always together.
Lipophilicity illustrates the trade-off. In a published set of matched molecular pairs, replacing OH with fluorine increased logP in 114 of 127 comparisons; replacing OMe with fluorine did so in 97 of 133. The remainder moved in the other direction. This is informative evidence about oxygen-to-fluorine substitutions—not a general estimate for hydrogen-to-fluorine replacement or a prediction of clinical success.
Figure 02
Oxygen-to-fluorine replacement does not move every pair in the same direction
Counts of matched molecular pairs with measured logP, grouped by direction of change. These counts do not indicate the magnitude of the logP change.
| Replacement | logP increased | logP decreased | Total pairs |
|---|---|---|---|
| OH → F | 114 | 13 | 127 |
| OMe → F | 97 | 36 | 133 |
Source: Glyn & Pattison, J. Med. Chem. 2021, Figure 1
Metabolism tells a similarly varied story. Obach and colleagues reported in vitro stability improvements for selected fluorinated analogues, including a 16-fold change in one risperidone example, while a fluorinated ramelteon analogue showed no improvement. The lesson is not that fluorine is unpredictable; it is that a credible hypothesis needs the right matched comparator and a relevant assay.
A measured property gain is the beginning of a development case, not its conclusion.
For teams assessing new analogues, this calls for a focused set of tests: the target property, the closest structural comparator, and the liabilities likely to move with it. A higher logP, for instance, is not automatically better when solubility and exposure also matter.
The route can change the economics of a promising molecule.
A useful fluorinated analogue may still be the wrong development choice if the key intermediate is difficult to access, the route depends on a fragile selectivity window, or purification erodes usable yield. Introducing fluorine early can simplify the installation step but carry a difficult fragment through the entire sequence. Late-stage fluorination may shorten a route while raising compatibility and impurity-control questions.
In published process work on voriconazole, a route to its fluoropyrimidine partner was redesigned from six steps to four. That result concerns a specific intermediate and should not be extrapolated to every fluorinated API. It does, however, show why route design—not simply reagent selection—can reshape the cost and practicality of supplying a target structure.
Fluorinated building blocks and fully perfluorinated specialty materials should not be treated as one market. The latter may introduce materially different environmental and regulatory considerations. For an examination of that separate supply challenge, see our perspective on specialty PFAS research materials.
The strongest candidates connect molecular performance to a workable supply route.
The most useful decision is not always whether to keep or discard a fluorinated structure. It is which uncertainty to resolve next. A medicinal chemistry team may need another matched analogue; a process group may need to test a different entry point; a sourcing team may need evidence that a specified intermediate can be supplied at a repeatable quality.
That alignment matters long before commercial manufacture. Moving from milligrams to grams or kilograms often changes which constraints dominate: impurity carry-through, isolation efficiency, starting-material dependence, or analytical burden. A better-looking molecule can become a weaker program if those questions are deferred until the route is already fixed.
